ATE429486T1 - Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten - Google Patents

Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten

Info

Publication number
ATE429486T1
ATE429486T1 AT02762780T AT02762780T ATE429486T1 AT E429486 T1 ATE429486 T1 AT E429486T1 AT 02762780 T AT02762780 T AT 02762780T AT 02762780 T AT02762780 T AT 02762780T AT E429486 T1 ATE429486 T1 AT E429486T1
Authority
AT
Austria
Prior art keywords
cell
antigen
growth factor
lymphocytes
binding
Prior art date
Application number
AT02762780T
Other languages
English (en)
Inventor
Hiroaki Sagawa
Mitsuko Ideno
Ikunoshin Kato
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of ATE429486T1 publication Critical patent/ATE429486T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/905—Hyaluronic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02762780T 2001-08-15 2002-08-15 Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten ATE429486T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001246747 2001-08-15
JP2001376966 2001-12-11
JP2002084428 2002-03-25
PCT/JP2002/008298 WO2003016511A1 (fr) 2001-08-15 2002-08-15 Procede permettant une culture etendue de lymphocytes t cytotoxiques specifiques d'un antigene

Publications (1)

Publication Number Publication Date
ATE429486T1 true ATE429486T1 (de) 2009-05-15

Family

ID=27347333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02762780T ATE429486T1 (de) 2001-08-15 2002-08-15 Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten

Country Status (9)

Country Link
US (1) US7910368B2 (de)
EP (2) EP1424387B1 (de)
JP (3) JP4949607B2 (de)
KR (2) KR100888915B1 (de)
CN (2) CN100510060C (de)
AT (1) ATE429486T1 (de)
DE (1) DE60232083D1 (de)
TW (3) TWI311586B (de)
WO (1) WO2003016511A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001278734A1 (en) * 2000-08-16 2002-02-25 Takara Bio Inc. Method of extensive culture of antigen-specific cytotoxic t cells
JP4949607B2 (ja) 2001-08-15 2012-06-13 タカラバイオ株式会社 抗原特異的細胞傷害性ｔ細胞拡大培養方法
KR100786054B1 (ko) * 2002-03-25 2007-12-17 다카라 바이오 가부시키가이샤 세포상해성 림프구의 제조방법
EA012520B1 (ru) * 2003-08-22 2009-10-30 Такара Био Инк. Способ получения цитотоксических лимфоцитов
KR101279172B1 (ko) 2005-08-17 2013-06-27 다카라 바이오 가부시키가이샤 림프구의 제조 방법
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
KR101408565B1 (ko) 2005-09-30 2014-06-17 다카라 바이오 가부시키가이샤 Ｔ 세포 집단의 제조 방법
US8216837B2 (en) 2006-06-09 2012-07-10 Takara Bio Inc. Method of producing lymphocytes
JPWO2008111430A1 (ja) * 2007-03-09 2010-06-24 タカラバイオ株式会社 γδＴ細胞集団の製造方法
JPWO2008143014A1 (ja) * 2007-05-11 2010-08-05 タカラバイオ株式会社 がん治療剤
WO2009119793A1 (ja) 2008-03-27 2009-10-01 タカラバイオ株式会社 遺伝子導入細胞の製造方法
EP2236517A1 (de) 2009-03-31 2010-10-06 Takara Bio, Inc. Monoklonaler Anti-Fibronektinfragment-Antikörper
EP2471901A4 (de) 2009-08-25 2013-06-26 Takara Bio Inc Verfahren zur herstellung einer t-zellen-population unter verwendung von retinsäure
KR101110866B1 (ko) * 2009-12-29 2012-02-20 재단법인 포항산업과학연구원 몰드 동판 가공 장치
US9670459B2 (en) * 2010-08-10 2017-06-06 Takara Bio Inc. Production method for cell populations
ES2746929T3 (es) * 2011-04-07 2020-03-09 Scripps Research Inst Cribado de alto rendimiento para compuestos que modulan los niveles de macromoléculas celulares
CN103013914B (zh) * 2012-12-13 2014-12-03 吉林省拓华生物科技有限公司 体外培养杀伤性t细胞的方法
US20150079626A1 (en) * 2013-03-19 2015-03-19 Lsip, Llc Method of obtaining a cell population containing cancer stem cells
EP3805371A1 (de) 2014-05-15 2021-04-14 National University of Singapore Modifizierte natürliche killerzellen und verwendungen davon
CA3056439A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11201908337VA (en) 2017-03-27 2019-10-30 Nat Univ Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
WO2020032179A1 (ja) * 2018-08-10 2020-02-13 国立大学法人京都大学 Ｃｄ３陽性細胞の製造方法
KR102839381B1 (ko) 2018-08-29 2025-07-28 내셔널 유니버시티 오브 싱가포르 유전적으로 변형된 면역 세포의 생존 및 확장을 특이적으로 자극하는 방법
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US5019646A (en) 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
JP2561131B2 (ja) 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5198423A (en) 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5188959A (en) 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
JP3104178B2 (ja) 1990-03-30 2000-10-30 寶酒造株式会社 機能性ポリペプチド
JPH04297494A (ja) 1991-03-26 1992-10-21 Fuji Photo Film Co Ltd ペプチド誘導体とその用途
JP2729712B2 (ja) 1991-04-23 1998-03-18 寳酒造株式会社 機能性ポリペプチド
JPH07102131B2 (ja) * 1991-07-15 1995-11-08 日本石油株式会社 ヒトリンパ球の癌細胞に対する傷害活性を高める方法
JPH06306096A (ja) 1993-02-26 1994-11-01 Fuji Photo Film Co Ltd ペプチド誘導体及びその用途
GB9315810D0 (en) 1993-07-30 1993-09-15 Univ London Stabilised materials
DE4336399A1 (de) 1993-10-26 1995-04-27 Augustinus Dr Med Bader Verfahren zur Verbesserung der Matrixbedingungen bipolar adhärierter Hepatozyten und zur Herstellung eines entsprechend konfigurierten Zellkulturkits
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE4412794A1 (de) * 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
GB9413029D0 (en) 1994-06-29 1994-08-17 Common Services Agency Stem cell immobilisation
CN1116549A (zh) * 1994-08-09 1996-02-14 中国医学科学院肿瘤研究所 新型高亲和性肿瘤杀伤细胞(t-ak细胞)制剂
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5824547A (en) 1994-11-29 1998-10-20 Takara Shuzo Co., Ltd. Method for production of transfected cells
WO1996016674A1 (en) * 1994-12-01 1996-06-06 New England Deaconess Hospital Corporation In vitro t-lymphopoiesis system
ATE292689T1 (de) 1995-05-04 2005-04-15 Us Navy Verbesserte verfahren zur transfektion der t- zellen
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
JPH0925299A (ja) 1995-07-13 1997-01-28 Sumitomo Electric Ind Ltd Ｃｄ４４リガンド
CA2227327A1 (en) 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1997011604A1 (en) * 1995-09-29 1997-04-03 Indiana University Foundation Methods for enhanced virus-mediated dna transfer using molecules with virus- and cell-binding domains
ES2259182T3 (es) 1995-11-13 2006-09-16 Takara Bio Inc. Metodo de introduccion de genes en celulas diana por medio de retrovirus.
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
WO1997032970A1 (en) * 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes
ATE476496T1 (de) * 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
AU728557B2 (en) 1996-09-23 2001-01-11 Ontogeny, Inc. Hematopoietic stem cells and methods for generating such cells
AU6140998A (en) 1997-01-31 1998-08-25 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
JP2002507387A (ja) * 1997-12-24 2002-03-12 コリクサ コーポレイション 乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
WO2000056368A1 (en) 1999-03-23 2000-09-28 Takara Shuzo Co., Ltd. Gene therapeutics
JP3904374B2 (ja) 2000-02-29 2007-04-11 独立行政法人科学技術振興機構 キラー活性を増強したリンパ球
AU2001278734A1 (en) * 2000-08-16 2002-02-25 Takara Bio Inc. Method of extensive culture of antigen-specific cytotoxic t cells
CN1314414A (zh) * 2001-03-16 2001-09-26 中国人民解放军第四军医大学 一种新的分子量为140kDa的活化T细胞表面抗原
JP4949607B2 (ja) 2001-08-15 2012-06-13 タカラバイオ株式会社 抗原特異的細胞傷害性ｔ細胞拡大培養方法
KR100786054B1 (ko) 2002-03-25 2007-12-17 다카라 바이오 가부시키가이샤 세포상해성 림프구의 제조방법

Also Published As

Publication number Publication date
EP2070542A2 (de) 2009-06-17
KR100888915B1 (ko) 2009-03-16
TW200718784A (en) 2007-05-16
US20050042208A1 (en) 2005-02-24
JP2008035864A (ja) 2008-02-21
TWI315740B (de) 2009-10-11
JP4472764B2 (ja) 2010-06-02
TW200626725A (en) 2006-08-01
KR20040030093A (ko) 2004-04-08
KR20070122579A (ko) 2007-12-31
EP1424387A1 (de) 2004-06-02
CN101633907B (zh) 2012-09-05
JP2008278892A (ja) 2008-11-20
CN100510060C (zh) 2009-07-08
EP1424387B1 (de) 2009-04-22
WO2003016511A1 (fr) 2003-02-27
CN1543501A (zh) 2004-11-03
US7910368B2 (en) 2011-03-22
DE60232083D1 (de) 2009-06-04
JP4332573B2 (ja) 2009-09-16
TWI311586B (en) 2009-07-01
CN101633907A (zh) 2010-01-27
EP1424387A4 (de) 2005-10-12
EP2070542A3 (de) 2010-01-06
JPWO2003016511A1 (ja) 2004-12-02
JP4949607B2 (ja) 2012-06-13
KR100858857B1 (ko) 2008-09-17

Similar Documents

Publication Publication Date Title
ATE429486T1 (de) Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
CY1110695T1 (el) Μεθοδοι για την δημιουργια υψηλου τιτλου ανευ-βοηθου παρασκευασματων απελευθερωμενων ανασυνδυασμενων aav φορεων
DE60034566D1 (de) Peptidakzeptor ligationsverfahren
SG152273A1 (en) Pdx1 expressing endoderm
ATE314395T1 (de) Humanisierte antikörper und verfahren zu ihrer herstellung
ATE459652T1 (de) Verfahren zur herstellung von antikörpern
DK1456346T3 (da) Nyt inducerbart genekspressionssystem baseret på ecdysonreceptor/invertebrat-retinoid-x-receptor
DK1399256T3 (da) Fremgangsmåde til aktivering af en katalysator omfattende en koboltforbindelse og en bærer
ATE513905T1 (de) Verfahren für die replikation von influenza in zellkultur, und die bei diesem verfahren hergestellten influenza viren
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE408017T1 (de) Verfahren zur rna und protein synthese
ATE506381T1 (de) Halogen-substituiertes katalysatorsystem zur olefinpolymerisation
TW200741000A (en) Method of producing lymphocytes
EA200600459A1 (ru) Способ получения цитотоксических лимфоцитов
ATE555194T1 (de) Methode zur herstellung von proliferierenden und differenzierenden zelllinien
ATE344321T1 (de) Verfahren zur aufreinigung von bakterienzellen und zellbestandteilen
WO1999050459A3 (en) High throughput in vitro screening assays for transcription modulators
HUP0204421A2 (en) Chemically-modified supports and supported catalyst systems prepared therefrom
DE60225312D1 (de) Samenspezifische 7s-alpha-promoter zur expression von genen in pflanzen
ATE416257T1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
ATE505535T1 (de) Verfahren zur herstellung stabiler b-lymphozyten
DE60136558D1 (de) Verfahren zur kultivierung humaner chondrozyten
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
EA200000483A1 (ru) Способ и устройство для выращивания (концентрирования) и исследования микробиологических проб
CY1109583T1 (el) Κυτοκινες θηλαστικων, αντιστοιχα αντιδραστηρια

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties